Whole-body MRI for the Detection of Metastasis
Withdrawn
- Conditions
- Breast CancerMetastases
- Registration Number
- NCT02183597
- Lead Sponsor
- Norwegian University of Science and Technology
- Brief Summary
Develop and optimize protocols for whole body MRI for detection of metastases. Evaluate diagnostic accuracy through application of optimized protocols for screening of cancer patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
- Cancer patient
Exclusion Criteria
- Poor general condition
- Pacemaker or other MRI contraindications
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of metastasis in skeleton Baseline and after 6 months Number of skeleton metastasis will be assessed at the regular clinical follow-up of breast cancer patients with metastatic disease
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do optimized whole-body MRI protocols in NCT02183597 enhance metastasis detection in breast cancer through molecular imaging techniques?
What is the comparative diagnostic accuracy of whole-body MRI versus standard-of-care imaging (CT/PET) for metastasis detection in NCT02183597?
Which biomarkers are associated with improved metastasis detection rates using whole-body MRI protocols in NCT02183597 breast cancer patients?
What are the potential adverse events and safety considerations of whole-body MRI in NCT02183597 compared to other imaging modalities?
How does the implementation of whole-body MRI in NCT02183597 impact the development of targeted therapies for HER2-positive and triple-negative breast cancer subtypes?